Bayer Paid Competitors $200mm to Keep Generic Cipro Off the Market; Suit Asks Court to Intercede, Nullify Agreement and Open the Way For Generics to Enter the Market: The Prescription Access Litigation (PAL) project announced today it has gone to court to dislodge an agreement between Bayer, Barr Laboratories, and two other generic drug companies that it says is blocking access to adequate supplies and cheaper, generic versions of Cipro, now the leading antibiotic used to treat Anthrax. Decrying the inadequacy of the arrangement that the federal government just negotiated with Bayer, consumer groups in eleven states – representing over one million consumers - have signed onto the litigation.